Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia
Author Information
Author(s): Saccà Francesco, Puorro Giorgia, Antenora Antonella, Marsili Angela, Denaro Alessandra, Piro Raffaele, Sorrentino Pierpaolo, Pane Chiara, Tessa Alessandra, Brescia Morra Vincenzo, Cocozza Sergio, De Michele Giuseppe, Santorelli Filippo M., Filla Alessandro
Primary Institution: Department of Neurological Sciences, University Federico II, Naples, Italy
Hypothesis
The study aims to analyze frataxin protein and mRNA levels in Friedreich Ataxia patients, carriers, and controls to understand their diagnostic potential.
Conclusion
The study found that frataxin protein and mRNA levels can effectively differentiate Friedreich Ataxia patients from healthy individuals, although there is significant overlap between groups.
Supporting Evidence
- Frataxin levels were significantly lower in Friedreich Ataxia patients compared to controls.
- mRNA expression was reduced to 19.4% in classic Friedreich Ataxia patients compared to controls.
- The study achieved 100% sensitivity and specificity in distinguishing classic Friedreich Ataxia patients from controls based on frataxin levels.
Takeaway
This study looked at blood samples from people with Friedreich Ataxia and found that measuring certain proteins can help tell if someone has the disease.
Methodology
The study enrolled patients and controls, measured frataxin protein levels using lateral-flow immunoassay, and quantified mRNA levels using real-time PCR.
Limitations
The study had a limited number of patients and could not predict late-onset Friedreich Ataxia based on protein and mRNA levels alone.
Participant Demographics
The study included 27 classic Friedreich Ataxia patients, 5 point mutation cases, 6 late-onset cases, 33 healthy carriers, and 30 healthy controls.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website